Case number# PHHY2015ES077427, is an initial spontaneous report received from a physician via other 
pharmaceutical company (Biogen) via e mail on 25 Jun 2015.
This report refers to an adult female patient. Medical history and concomitant medication were not reported. The 
patient was on Tysabri (natalizumab) before Gilenya, as the case was received from Biogen.
The patient received Gilenya (fingolimod) capsule for an unknown indication from an unknown start date at an 
unknown dose, frequency and route of administration.
On an unknown date, the patient was suspicion of PML (progressive multifocal leukoencephalopathy) and was 
hospitalized. Action taken with Gilenya was unknown.
The outcome and causality of the event were not reported. The seriousness of the event was reported as medically 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 100 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
significant.